Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| ESPERITE (ESP) announces termination of negotiations regarding proposed sale of stem cell banking business to PBKM | ||
| By: Nasdaq / GlobeNewswire - 25 Jun 2019 | Back to overview list |
|
| Amsterdam, The Netherlands – 25 June 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Sale) has been terminated by PBKM. The terms of the Proposed Sale agreed between the respective executive boards of the parties did not receive approval by the supervisory board of PBKM. The board of directors of Esperite continues its evaluation of a broad range of strategic alternatives for its stem cell banking business and will seek reimbursement by PBKM for the legal costs incurred by Esperite during the negotiations of the Proposed Sale. About ESPERITE ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000. *** This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation). Attachment |
||
|
||
 | Back to overview list | |